Minerva Neurosciences Inc (NERV) was Resumed by Jefferies to “Buy”. Jefferies advised their investors in a research report released on May 12, 2016.
Minerva Neurosciences Inc closed down -0.16 points or -2.44% at $6.39 with 68,142 shares getting traded on Tuesday. Post opening the session at $6.51, the shares hit an intraday low of $6.18 and an intraday high of $6.52 and the price fluctuated in this range throughout the day.Shares ended Tuesday session in Red.
In a different news, on Mar 18, 2016, David Kupfer (director) purchased 181,488 shares at $5.51 per share price.
Minerva Neurosciences Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of a portfolio of product candidates to treat patients suffering from central nervous system (CNS) diseases. Its lead product candidate is MIN-101 a compound for the potential treatment of patients with schizophrenia. Its product pipeline also includes MIN-117 MIN-202 and MIN-301. MIN-101 is a compound it is developing for the treatment of patients with schizophrenia. MIN-117 is a compound for the potential treatment of patients suffering from major depressive disorder (MDD). MIN-202 is a selective orexin 2 receptor antagonist it is developing in collaboration with Janssen for the treatment of insomnia. MIN-301 is a soluble recombinant form of the Neuregulin-1b1 (NRG-1b1) protein for the treatment of Parkinson’s disease.